In this study, we demonstrated that Brazilin effectively inhibits cell proliferation in NSCLC cells with KRAS mutations in a concentration‐dependent manner, highlighting its potential as a therapeutic agent against these malignancies. This evidence concerns the gene KRAS and non-small cell lung carcinoma.